• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

    9/4/25 8:00:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COYA alert in real time by email

    NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for people living with ALS;

    Following FDA's recent acceptance of the COYA 302 IND, Coya plans to initiate its Phase 2 study in people with ALS in Q4 2025;

    The COYA 302 study will be presented during the NEALS Educational Webinar on September 29, 2025.

    HOUSTON, Sept. 4, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that its upcoming Phase 2 clinical trial to evaluate the efficacy and safety of COYA 302 in patients with ALS has been accepted as a NEALS-Affiliated Trial by the NEALS Consortium.

    Coya Therapeutics Logo (PRNewsfoto/Coya Therapeutics, Inc.)

    The NEALS Consortium is the world's largest ALS research network, comprising a highly active group of trial-ready sites with deep expertise in designing and managing FDA-regulated clinical studies. For more than 30 years, NEALS has partnered successfully with both industry and academic investigators to conduct high-quality ALS trials, guided by a seasoned leadership team committed to accelerating treatment development for people living with ALS.

    As a NEALS-affiliated study, the COYA 302 Phase 2 clinical trial will benefit from broad support across NEALS' institutional and community networks, enhancing operational execution and maximizing clinical impact. The study will be presented on September 29, 2025, during the NEALS Educational Webinar by James Berry, MD, MPH — Winthrop Family Scholar in ALS Sciences, Averill Healey Endowed Chair in ALS, and Chief of the Division of ALS and Motor Neuron Diseases at Mass General Hospital.

    "We are honored that our COYA 302 trial has been recognized by NEALS and look forward to working closely with their network of leading ALS investigators, clinical centers, and patient outreach groups," said Dr. Fred Grossman, President and Chief Medical Officer. "This important affiliation further advances our commitment to advancing new treatments for people living with ALS."

    Dr. Berry stated, "The COYA 302 trial represents an innovative approach to ALS treatment through its focus on enhancing regulatory T cell function. The affiliation of this Phase 2 trial with NEALS underscores the potential significance of Coya's therapeutic approach for the ALS community. We are pleased to present this study during our NEALS Educational Webinar."

    About COYA 302

    COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 is comprised of proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS. These mechanisms may have additive or synergistic effects.

    COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.

    About Amyotrophic Lateral Sclerosis

    Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons, the nerve cells in the brain and spinal cord that control voluntary muscle movement.  About 20,000 people live with ALS in the United States and approximately 5,000 new cases are diagnosed every year.  The disease is progressive, meaning the symptoms get worse over time. The functional status of ALS patents declines about 1 point per month on average, as measured by the Revised ALS Function Rating Scale1, or ALSFRS-R, a validated tool to monitor the progression of the disease.  ALS has no cure, and the currently approved drug treatments provide limited benefit to patients.  ALS is a type of motor neuron disease. As motor neurons degenerate and die, they stop sending messages to the muscles, which causes the muscles to weaken, start to twitch (fasciculations), and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. Most people with ALS die from respiratory failure, usually within three to five years from when the symptoms first appear.2

    1. Atassi N, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology, 2014;83:1719–1725. doi: 10.1212/WNL.0000000000000951.
    2. National Institutes of Health (NIH) Website (https://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis-als), accessed on January 4, 2023.

    About the NEALS Consortium

    Founded in 1995, NEALS (neals.org) is a global network of over 150 research centers, including over 100 clinical trial sites in the US and Canada, dedicated to developing and conducting clinical trials for amyotrophic lateral sclerosis (ALS) and related motor neuron diseases. NEALS has been recognized for its contributions to ALS research, notably in trials that have slowed ALS progression and improved patient survival. It offers an online database of ALS clinical trials, provides support to individuals with ALS and their families, and offers educational programs, such as the ALS Clinical Research Learning Institute. 

    About Coya Therapeutics, Inc.

    Headquartered in Houston, TX, Coya Therapeutics, Inc. (NASDAQ:COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

    Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

    For more information about Coya, please visit www.coyatherapeutics.com 

    Forward-Looking Statements

    This press release contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements.

    Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

    We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    Investor Contact 

    David Snyder, CFO

    [email protected]

    astr partners

    Matthew Beck

    [email protected] 

    917-415-1750

    Media Contacts

    Russo Partners

    Olipriya Das

    [email protected] 

    646-942-5588

    Matthew Purcell

    [email protected] 

    646-942-5595

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/coya-therapeutics-coya-302-als-trial-accepted-by-neals-as-a-neals-affiliated-trial-302545863.html

    SOURCE Coya Therapeutics, Inc.

    Get the next $COYA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COYA

    DatePrice TargetRatingAnalyst
    7/9/2025$16.00Buy
    Lake Street
    12/4/2024$15.00Buy
    D. Boral Capital
    More analyst ratings

    $COYA
    SEC Filings

    View All

    SEC Form 8-K filed by Coya Therapeutics Inc.

    8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

    9/2/25 8:30:25 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Coya Therapeutics Inc.

    EFFECT - Coya Therapeutics, Inc. (0001835022) (Filer)

    8/20/25 12:15:18 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B7 filed by Coya Therapeutics Inc.

    424B7 - Coya Therapeutics, Inc. (0001835022) (Filer)

    8/19/25 4:30:31 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

    NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for people living with ALS; Following FDA's recent acceptance of the COYA 302 IND, Coya plans to initiate its Phase 2 study in people with ALS in Q4 2025; The COYA 302 study will be presented during the NEALS Educational Webinar on September 29, 2025. HOUSTON, Sept. 4, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative

    9/4/25 8:00:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

    Q&A Highlights FDA IND Clearance, Partnerships, and 2025 Milestones Across ALS and Neurodegeneration Programs NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Arun Swaminathan, Chief Executive Officer of Coya Therapeutics, Inc. ("Coya" or the "Company") (NASDAQ:COYA), a clinical-stage biotechnology company developing Treg-modulating therapies to address ALS and other neurodegenerative diseases. Arun Swaminathan, CEO, Coya Therapeutics, Inc. In the interview, Mr. Swaminathan discusses Coya's recent progress and strategic vision, including: FDA acceptance of the Investigational New Drug (IND) application for COYA 302 in amyotrophic latera

    9/3/25 11:50:35 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coya Therapeutics to Participate at Upcoming September Investor Conferences

    HOUSTON, Sept. 3, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company's management team will participate in two upcoming investor conferences this month. H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 10, 2025Time: 10 am ETFormat: Presentation by Arun Swaminathan, Ph.D., CEO of Coya TherapeuticsLocation: Lotte New York Palace Hotel (455

    9/3/25 8:34:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goldstein Dov A Md exercised 17,557 shares at a strike of $1.09, increasing direct ownership by 176% to 27,557 units (SEC Form 4)

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    8/19/25 4:01:23 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Weinand Dieter

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    2/25/25 9:30:04 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ross Wilbur L Jr

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    2/25/25 9:30:03 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Snyder David S bought $12,934 worth of shares (1,800 units at $7.19), increasing direct ownership by 26% to 8,800 units (SEC Form 4)

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    11/14/24 6:08:32 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Swaminathan Arun bought $36,797 worth of shares (5,000 units at $7.36), increasing direct ownership by 100% to 10,000 units (SEC Form 4)

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    11/13/24 4:05:16 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Grossman Fred bought $19,973 worth of shares (2,710 units at $7.37) (SEC Form 4)

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    11/12/24 6:03:34 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Coya Therapeutics with a new price target

    Lake Street initiated coverage of Coya Therapeutics with a rating of Buy and set a new price target of $16.00

    7/9/25 8:41:23 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital initiated coverage on Coya Therapeutics with a new price target

    D. Boral Capital initiated coverage of Coya Therapeutics with a rating of Buy and set a new price target of $15.00

    12/4/24 7:30:44 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Leadership Updates

    Live Leadership Updates

    View All

    Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

    Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

    5/8/25 5:00:00 AM ET
    $COYA
    $REPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

    BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

    4/17/25 7:00:00 AM ET
    $AVIR
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.

    Secretary Ross has over 55 years' experience as a business leader, banker, and investor and is the former Chairman and Chief Strategy Officer of WL Ross & Co. Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Secretary Wilbur Ross to its board of directors, effective immediately. Coya intends to leverage Secretary Ross's extensive experience in both the business and investment community to help guide strategic partnering activities, capital markets initiatives and drug development programs. S

    12/20/23 8:30:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Financials

    Live finance-specific insights

    View All

    Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results will be presented simultaneously via a poster on Tuesday, October 29, at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The Phase 2 study was led by KOLs Dr. Alireza Faridar and Dr. Stanley

    10/28/24 8:00:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the third quarter ended September 30, 2023, and provided a clinical and business update. Q3 2023 and Recent Highlights Completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of Low Dose IL-2 in patients with mild-to-moderate Alzheimer's Disease (AD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at the Houston Methodist Hospital and is funded by the Gates Foundation and Alzheimer's As

    11/8/23 9:00:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update. Q2 2023 and Recent Highlights Presented positive results from a proof-of-concept (PoC), open-label, investigator-initiated clinical study of low dose interleukin-2 (ld IL-2) + CTLA4 Ig in Amyotrophic Lateral Sclerosis (ALS) illustrating enhancement of Treg function during the treatment period, halting of disease progression at 24 weeks and minimal decline a

    8/8/23 7:00:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

    SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

    11/12/24 3:37:54 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

    SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

    11/4/24 1:27:32 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

    SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

    11/4/24 11:42:58 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care